Eltoprazine - Elto Pharma
Alternative Names: DU-28853; EltoprazineLatest Information Update: 23 Feb 2022
At a glance
- Originator Solvay
- Developer Elto Pharma; PsychoGenics; Solvay
- Class Antidepressants; Antipsychotics; Piperazines; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor agonists; Serotonin 1B receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Aggression; Attention-deficit hyperactivity disorder; Cognition disorders; Drug-induced dyskinesia
- Discontinued Psychotic disorders
Most Recent Events
- 23 Feb 2022 No development reported - Phase-II for Aggression (In the elderly) in USA (PO)
- 23 Feb 2022 No development reported - Phase-II for Drug-induced dyskinesia in Sweden (PO)
- 23 Feb 2022 No development reported - Phase-II for Drug-induced dyskinesia in USA (PO)